ASCO Presentations Offer New Insights Into Role Of nab-Chemotherapy Based Breast Cancer Chemotherapy Treatment

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab) driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.